Managing menopausal symptoms in patients with hormone receptor-positive gynecologic cancers

Cover Page

Cite item

Full Text

Abstract

Young women with reproductive tract neoplasms who receive treatment leading to termination of ovarian function often suffer from menopause symptoms that contribute to dramatic drop in quality of life. Climacteric symptoms in women with iatrogenic menopause are more severe than in case of natural menopause, especially in women with reproductive tract neoplasms. They lead to dramatic drop in quality of life and are one of the main reasons to stop applying endocrine therapy in women with hormone-positive tumors, which leads to decrease in disease free survival and to decline the prognosis. The most effective treatment option for climacteric symptoms of moderate to severe degrees is menopause hormone therapy; however, such therapy is not suitable for patients with estrogen-dependent tumors in past medical history due to the likelihood risk of progression of cancer, as well as the risk of venous thrombosis, the frequency of which in cancer patients increases. Non-hormonal pharmacological and non-pharmacological correction methods are used as first-line therapy for menopause disorders in women with estrogen-dependent tumors of the reproductive system. Among non-hormonal non-pharmacological correction methods actively study such methods as acupuncture, yoga, exercise to control weight, and a diet rich in phytoestrogens. The most effective non-hormonal methods of correcting vasomotor symptoms are serotonin and norepinephrine reuptake inhibitors. However, currently in Russia these drugs can be prescribed only by a psychiatrist. The finding of effective and safe non-hormonal methods to correct menopause symptoms in women with hormone-positive reproductive tract tumors is the important task in practice among doctors in different specialties.

About the authors

O. V. Shabalova

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Author for correspondence.
Email: olga.shabalova93@gmail.com
ORCID iD: 0000-0001-5957-4584

Graduate Student, Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Russian Federation, Moscow

S. V. Yureneva

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: syureneva@gmail.com
ORCID iD: 0000-0003-2864-066X
Russian Federation, Moscow

S. V. Khokhlova

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: s_hohlova@oparina4.ru
ORCID iD: 0000-0002-4121-7228

D. Sci. (Med.), Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Russian Federation, Moscow

Zh. R. Gardanova

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology; Pirogov Russian National Research Medical University

Email: zanna7777@inbox.ru
ORCID iD: 0000-0002-9796-0846

D. Sci. (Med.), Prof., Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Pirogov Russian National Research Medical University

Russian Federation, Moscow

E. I. Ermakova

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: ermakova.health@mail.ru
ORCID iD: 0000-0002-6629-051X

Cand. Sci. (Med.), Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Russian Federation, Moscow

References

  1. Всемирная организация здравоохранения. Рак. https://www.who.int/ru/news-room/fact-sheets/detail/cancer
  2. [Vsemirnaia organizatsiia zdravookhraneniia. Rak. https://www.who.int/ru/news-room/fact-sheets/detail/cancer (in Russian).]
  3. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019.
  4. [Malignant neoplasms in Russia in 2018 (morbidity and mortality). Ed. A.D. Kaprina, V.V. Starinsky, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2019 (in Russian).]
  5. Siegel R, Miller K, Jemal A. Cancer statistics. CA Cancer J Clin 2017; 67 (1): 7–30. doi: 10.3322/caac.21387
  6. Колядина И.В., Поддубная И.В., Комов Д.В. Скрининг рака молочной железы: мировой опыт и перспективы. Рос. онкол. журн. 2015; 20 (1): 42–6.
  7. [Koliadina I.V., Poddubnaya I.V., Komov D.V. Skrining raka molochnoi zhelezy: mirovoi opyt i perspektivy. Ros. onkol. zhurn. 2015; 20 (1): 42–6 (in Russian).]
  8. Колядина И.В., Поддубная И.В. Современные возможности терапии HER2-положительного рака молочной железы (по материалам клинических исследований). ¬Современная онкология. 2014; 16 (4): 10–20.
  9. [Kolyadina I.V., Poddubnaya I.V. Current treatment options for HER2-positive breast cancer (based on clinical studies). Journal of Modern Oncology. 2014; 16 (4): 10–20 (in Russian).]
  10. Колядина И.В., Поддубная И.В., Van D.V.C.J.H. и др. Хирургическое лечение «раннего» рака молочной железы: что изменилось? Опыт международного сотрудничества. Сиб. онкол. журн. 2013; 2: 67–71.
  11. [Koliadina I.V., Poddubnaya I.V., Van D.V.C.J.H. et al. Khirurgicheskoe lechenie «rannego’ raka molochnoi zhelezy: chto izmenilos’? Opyt mezhdunarodnogo sotrudnichestva. Sib. onkol. zhurn. 2013; 2: 67–71 (in Russian).]
  12. Хохлова С.В., Базаева И.Я. Оптимальная тактика адъювантного лечения больных раком тела матки. Фарматека. 2017; 8 (341): 29–35.
  13. [Khokhlova S.V., Bazaeva I.Ia. Optimal’naia taktika ad»iuvantnogo lecheniia bol’nykh rakom tela matki. Farmateka. 2017; 8 (341): 29–35 (in Russian).]
  14. Хохлова С.В. Новые возможности повышения результатов терапии рака шейки матки. Мед. оппонент. 2019; 1 (5): 18–25.
  15. [Khokhlova S.V. Novye vozmozhnosti povysheniia rezul’tatov terapii raka sheiki matki. Med. opponent. 2019; 1 (5): 18–25 (in Russian).]
  16. Колядина И.В., Поддубная И.В., Трофимова О.П. и др. Прогностическое значение локального и системного лечения при раке молочной железы I стадии. Современная онкология. 2013; 15 (3): 33–40.
  17. [Kolyadina I.V., Poddubnaya I.V., Trofimova O.P. et al. Prognostic value of local and systemic treatment for stage I breast cancer. Journal of Modern Oncology. 2013; 15 (3): 33–40 (in Russian).]
  18. Хохлова С.В. Место бевацизумаба в лечении больных раком яичников и раком шейки матки. Современная онкология. 2017; 19 (1): 34–41.
  19. [Khokhlova S.V. The place of bevacizumab in the treatment of patients with ovarian cancer and cervical cancer. Journal of Modern Oncology. 2017; 19 (1): 34–41 (in Russian).]
  20. Хохлова С.В. Олапариб в поддерживающем режиме лечения больных раком яичников с платиночувствительным рецидивом. Современная онкология. 2017; 19 (3): 13–8.
  21. [Khokhlova S.V. Olaparib in a supportive treatment regimen for patients with ovarian cancer with platinum-sensitive relapse. Journal of Modern Oncology. 2017; 19 (3): 13–8 (in Russian).]
  22. Колядина И.В., Поддубная И.В., Трофимова О.П. и др. Биология опухоли или адъювантная системная терапия что определяет риск развития рецидива при раке молочной железы I стадии. Современная онкология. 2014; 16 (4): 24–30.
  23. [Kolyadina I.V., Poddubnaya I.V., Trofimova O.P. et al. Tumor biology or adjuvant systemic therapy that determines the risk of relapse in stage I breast cancer. Journal of Modern Oncology. 2014; 16 (4): 24–30 (in Russian).]
  24. Хохлова С.В. Выбор адъювантного лечения при раке эндометрия. Мед. оппонент. 2019; 1 (5): 44–51.
  25. [Khokhlova S.V. Vybor ad»iuvantnogo lecheniia pri rake endometriia. Med. opponent. 2019; 1 (5): 44–51 (in Russian).]
  26. Bernhard J, Luo W, Ribi K et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol 2015; 16 (7): 848–58. doi: 10.1016/S1470-2045(15)00049-2
  27. LHRH-agonists in Early Breast Cancer Overview Group, Cuzick J, Ambroisine L, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369: 1711–23. doi: 10.1016/S0140-6736(07)60778-8
  28. Sonigo C, Beau I, Binart N et al. The Impact of Chemotherapy on the Ovaries: Molecular Aspects and the Prevention of Ovarian Damage. Int J Mol Sci 2019; 20 (21): 5342.
  29. doi: 10.3390/ijms20215342
  30. Bedoschi G, Navarro PA, Oktay K. Chemotherapy induced damage to ovary: mechanisms and clinical impact. Future Oncol 2016; 12 (20): 2333–44. doi: 10.2217/fon-2016-0176
  31. So-Youn Kim, Geum Joon Cho, Davis JS. Consequences of chemotherapeutic agents on primordial follicles and future clinical applications. Obstet Gynecol Sci 2019; 62 (6): 382–90. doi: 10.5468/ogs.2019.62.6.382
  32. Han H-S, Ro J, Lee KS et al. Analysis of chemotherapyinduced amenorrhea rates by three different anthracycline and taxane containing regimen for early breast cancer. Breast Cancer Res Treat 2009; 115 (2): 335–42. doi: 10.1007/s10549-008-0071-9
  33. Partridge AH, Ruddy KJ. Fertility and adjuvant treatment in young women with breast cancer. Breast 2007; 16 (Suppl. 2): S175–81. doi: 10.1016/j.breast.2007.07.029
  34. Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol 2008; 26 (5): 753–8. doi: 10.1200/JCO.2007.14.1655
  35. Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med 2009; 360 (9): 902–11. DOI: 10.1056/ ¬NEJMra0801454
  36. Tiong V, Rozita AM, Taib NA et al. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer. World J Surg 2014; 38 (9): 2288–96. doi: 10.1007/s00268-014-2542-y
  37. Jae Jun Shin, Young Min Choi, Jong Kwan Jun et al. Amenorrhea and Menopause in Patients with Breast Cancer after Chemotherapy. J Breast Cancer 2019; 22 (4): 624–34. doi: 10.4048/jbc.2019.22.e53
  38. Vriens IJ, De Bie AJ, Aarts MJ et al. The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients. Oncotarget 2017; 8 (7): 11372–9. doi: 10.18632/oncotarget.14532
  39. Torino F, Barnabei A, De Vecchis L et al., Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. Crit Rev Oncol Hematol 2014; 89 (1): 27–42. doi: 10.1016/j.critrevonc.2013.07.007
  40. Di Cosimo S, Alimonti A, Ferretti G et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol 2004; 15: 1065–71. doi: 10.1093/annonc/mdh266
  41. Pinkerton JV, Santen RJ. Managing vasomotor symptoms in women after cancer. Climacteric 2019. doi: 10.1080/13697137.2019.1600501
  42. Marino JL, Saunders CM, Emery LI et al. Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history. Menopause 2014; 21: 267–74. doi: 10.1097/GME.0b013e3182976f46
  43. Carter J, Stabile C, Gunn A, Sonoda Y. The physical consequences of gynecologic cancer surgery and theirimpact on sexual, emotional, and quality of life issues. J Sex Med 2013; 10 (Suppl. 1): 21–34. doi: 10.1111/jsm.12002
  44. Murphy CC, Bartholomew LK, Carpentier MY et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 2012; 134 (2): 459–78. doi: 10.1007/s10549-012-2114-5
  45. Hershman DL, Shao T, Kushi LH et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011; 126 (2): 529–37. DOI: 10. 1007/s10549-010-1132-4
  46. Harlow SD, Gass M, Hall JE et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric 2012; 15: 105–14. doi: 10.1097/gme.0b013e31824d8f40
  47. Avis NE, Crawford SL, Greendale G et al. Study of Women’s Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175: 531–9. doi: 10.1001/jamainternmed.2014.8063
  48. Nappi RE, Palacios S, Bruyniks N et al, EVES Study investigators. The burden of vulvovaginal atrophy on women’s daily living: implications on quality of life from a face-to-face reallife survey. Menopause 2019; 26: 485–91. doi: 10.1097/GME.0000000000001260
  49. Nunns D et al. The morbidity of surgery and adjuvant radiotherapy in the management of endometrial cancer. Int J Gynecol Cancer 2000; 10 (3): 233–8. doi: 10.1046/j.1525-1438. 2000.010003233.x
  50. Zeng YC, Li Q, Li X, Loke AY. Chinese women’s sexuality concerns after gynecologic cancer. Cancer Nurs 2012; 35 (4): 257–64. doi: 10.1097/NCC.0b013e31822f65e9
  51. Sears CS, Robinson JW, Walker LM. A comprehensive review of sexual health concerns after cancer treatment and the biopsychosocial treatment options available to female patients. Eur J Cancer Care (Engl) 2018; 27 (2): e12738. doi: 10.1111/ecc.12738
  52. Yingchun Zeng, Cheng ASK, Ting Song et al. Effects of Acupuncture on Cancer-Related Cognitive Impairment in Chinese Gynecological Cancer Patients: A Pilot Cohort Study. Integr Cancer Ther 2018; 17 (3): 737–46. doi: 10.1177/1534735418777109
  53. Roberts K, Chong T, Hollands E et al. Screening for sexual health concerns in survivors of gynecological cancer. Support Care Cancer 2020; 28 (2): 599–605. doi: 10.1007/s00520-019-04872-4
  54. Forner DM, Dakhil R, Lampe B. Quality of life and sexual function after surgery in early stage vulvar cancer. Eur J Surg Oncol 2015; 41 (1): 40–5. doi: 10.1016/j.ejso.2014.10.050
  55. Onujiogu N et al. Survivors of endometrial cancer: who is at risk for sexual dysfunction? Gynecol Oncol 2011; 123 (2): 356–9. doi: 10.1016/j.ygyno.2011.07.035
  56. Marsden J, Marsh M, Rigg A, British Menopause Society. British Menopause Society consensus statement on the management of estrogen deficiency symptoms, arthralgia and menopause diagnosis in women treated for early breast cancer. Post Reprod Health 2019; 25: 21–32. doi: 10.1177/2053369118824920
  57. Zhang Q, Li F, Zhang H et al. Effects of nurse-led home-based exercise & cognitive behavioral therapy on reducing cancer-related fatigue in patients with ovarian cancer during and after chemotherapy: A randomized controlled trial. Int J Nurs Stud 2018; 78: 52–60. doi: 10.1016/j.ijnurstu.2017.08.010
  58. Elkins GR, Fisher WI, Johnson AK et al. Clinical hypnosis in the treatment of postmenopausal hot flashes. a randomized controlled trial. Menopause 2013; 20: 291–8. doi: 10.1097/GME. 0b013e31826ce3ed
  59. Wang XP, Zhang DJ, Wei XD et al. Acupuncture for the relief of hot flashes in breast cancer patients: a systematic review and meta-analysis of randomized controlled trials and observational studies. J Can Res Ther 2018; 14: 600–8. doi: 10.4103/0973-1482.183174
  60. Liu W, Qdaisat A, Lopez G et al. Acupuncture for Hot Flashes in Cancer Patients: Clinical Characteristics and Traditional Chinese Medicine Diagnosis as Predictors of Treatment Response. Integr Cancer Ther 2019; 18: 1534735419848494. doi: 10.1177/1534735419848494
  61. Caan BJ, Emond JA, Su HI et al. Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer survivors. J Clin Oncol 2012; 30: 1492–7. doi: 10.1200/JCO.2011.36.8597
  62. Lee MS, Kim JI, Ha JY et al. Yoga for menopausal symptoms: a systematic review. Menopause 2009; 16: 602–8. doi: 10.1097/gme.0b013e31818ffe39
  63. Daley A, Stokes-Lampard H, Thomas A et al. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2014; (11): CD006108. doi: 10.1002/14651858.CD006108.pub4
  64. Newton KM, Reed SD, Guthrie KA et al. Efficacy of yoga for vasomotor symptoms: a randomized controlled trial. Menopause 2014; 21: 339–46. doi: 10.1097/GME.0b013e31829e4baa
  65. Lampe JW. Isoflavonoid and lignan phytoestrogens as dietary biomarkers. J Nutr 2003; 133 (Suppl. 3): 956S–964S. doi: 10.1093/jn/133.3.956S
  66. Lethavy A, Marjoribanks J, Kronenberg F et al. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev 2013; 12. doi: 10.1002/14651858.CD001395.pub4
  67. Winther K, Rein E, Hedman C. Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study. Climacteric 2005; 8 (2): 162–70. doi: 10.1080/13697130500117987
  68. Goldstein SR, Espié M, Druckmann R. Does purified Swedish pollen extract, a nonhormonal treatment for vasomotor symptoms, inhibit the CYP2D6 enzyme system? Menopause 2015; 22: 1212–4. doi: 10.1097/GME.0000000000000535
  69. Drewe J, Bucher KA, Zahner C. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. Springer Plus 2015; 4: 65. doi: 10.1186/s40064-015-0808-y
  70. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev 2012; 9: CD007244. doi: 10.1002/14651858.CD007244.pub2
  71. Беляев А.М. и др. Онкопсихология для врачей-онкологов и медицинских психологов. Руководство. Издание 2-е, доп. Под ред. А.М. Беляева, В.А. Чулковой, Т.Ю. Семиглазовой, М.В. Рогачева. СПб.: АНО «Вопросы онкологии», 2018.
  72. [Belyaev A.M. et al. Oncopsychology for oncologists and medical psychologists. Leadership. 2nd edition, add. Ed. A.M. Belyaev, V.A. Chulkova, T.Yu. Semiglazova, M.V. Rogachev. Saint Petersburg: ANO «Voprosy onkologii», 2018 (in Russian).]
  73. Shams T, Firwana B, Habib F et al. SSRIs for hot flashes: a systematic review and meta analysis of randomized trials. J Gen Intern Med 2013; 29 (1): 204–13. doi: 10.1007/s11606-013-2535-9
  74. The North American Menopause Society. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015; 22: 1155–74. doi: 10.1097/GME.0000000000000546
  75. Handley AP, Williams M. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. J Am Assoc Nurse Pract 2015; 27 (1): 54–61. doi: 10.1002/2327-6924.12137
  76. Capriglione S, Plotti F, Montera R et al. Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial. Gynecol Oncol 2016; 143: 584–8. doi: 10.1016/j.ygyno.2016.10.006
  77. Simon JA, Portman DJ, Kaunitz AM et al. Low-dose paroxetine 7.5mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013; 20: 1027–35. doi: 10.1097/GME.0000000000000210
  78. Stearns V, Slack R, Greep N et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. JCO 2005; 23: 6919–30. doi: 10.1200/JCO.2005.10.081
  79. Barton DL, LaVasseur BI, Sloan JA et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010; 28: 3278–83. doi: 10.1200/JCO.2009.26.6379
  80. Freeman EW, Guthrie KA, Caan B et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011; 305: 267–74. doi: 10.1001/jama.2010.2016
  81. Loprinzi CL, Sloan JA, Perez EA et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20 (6): 1578–83. https://doi.org/10.1200/JCO.2002.20.6.1578
  82. Loprinzi CL, Kugler JW, Sloan JA et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356: 2059–63. doi: 10.1016/S0140-6736(00)03403-6
  83. Joffe H, Guthrie KA, LaCroix AZ et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014; 174: 1058–66. doi: 10.1001/jamainternmed.2014.1891
  84. Leon-Ferre RA et al. Management of hot flashes in women with breast cancer receiving ovarian function suppression. Cancer Treat Rev 2017; 52: 82–90. doi: 10.1016/j.ctrv.2016.11.012
  85. Johnson MD, Zuo H, Lee K‐H et al. Pharmacological characterization of 4‐hydroxy‐N‐desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004; 85: 151–9. doi: 10.1023/B:BREA.0000025406.31193.e8
  86. Reddy SY, Warner H, Guttuso T Jr et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006; 108: 41–8. doi: 10.1097/01.AOG. 0000222383.43913.ed
  87. Bockbrader HN, Radulovic LL, Posvar EL et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol 2010; 50: 941–50. doi: 10.1177/0091270009352087
  88. Lee YK, Chung HH, Kim JW et al. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: A randomized controlled trial. Obstet Gynecol 2011; 117: 922–7. doi: 10.1097/AOG.0b013e3182118790
  89. Jokar A, Davari T, Asadi N et al. Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: A randomized controlled clinical trial. Int J Community Based Nurs Midwifery 2016; 4 (1): 69–78.
  90. Lester J, Pahouja G, Andersen B et al: Atrophic vaginitis in breast cancer survivors: A difficult survivorship issue. J Pers Med 2015; 5: 50–66. doi: 10.3390/jpm5020050
  91. WHO. Use and procurement of additional lubricants for male and female condoms: WHO/UNFPA/FHI360 – advisory note. 2012.
  92. Hickey M, Marino J, Braat S, Wong S. A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer. Breast Cancer Res Treat 2016; 158: 79–90. doi: 10.1007/s10549-016-3865-1
  93. Marino J, McNamara H, Hickey M. Managing menopausal symptoms after cancer: an evidence-based approach for primary care. Med J Aust 2018; 208: 127–32. doi: 10.5694/mja17.00693
  94. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturiser composition? Climacteric 2016; 19: 151–61. doi: 10.3109/13697137.2015.1124259

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies